Freeze-dried mRNA vaccines stay stable for 4 months at fridge temperature
This week brought major breakthroughs in making mRNA vaccines more accessible worldwide, plus advances in targeting cancer cells and understanding how our immune systems respond to these revolutionary therapies.
๐ง Freeze-drying could eliminate cold-chain requirements for mRNA vaccines
Scientists developed freeze-dried mRNA vaccine formulations that remained stable and functional for 4 months at refrigerator temperature (4ยฐC), compared to current vaccines that require ultra-cold storage
The best-performing formulation used 20% sucrose with Tris buffer, maintaining over 90% encapsulation efficiency and preserving particle size around 200 nm after reconstitution
At room temperature (20ยฐC), the formulations showed progressive destabilization over 6 months, but one sucrose-based version retained acceptable stability
Why it matters: Current mRNA vaccines require expensive ultra-cold storage (-70ยฐC), limiting global distribution especially in low-resource settings. This freeze-drying approach could make mRNA vaccines as easy to store and distribute as traditional vaccines.
Key Findings
๐ฏ New enzyme method detects thousands of RNA modifications with enhanced precision
Researchers developed ELAP-seq, which uses a naturally occurring enzyme from an ancient microorganism to tag pseudouridine modifications in RNA with single-nucleotide resolution
The method identified thousands of candidate pseudouridine sites in human HeLa and HEK 293T cells with markedly enhanced signal-to-noise ratio
Unlike previous techniques, this approach reduces sequencing and computational demands while providing high sensitivity and specificity
๐ฌ Circular RNA emerges as more stable vaccine platform than linear mRNA
Circular RNA vaccines demonstrated sustained antigen availability and robust immune responses due to their covalently closed structure, which enhances molecular stability compared to linear mRNA
These vaccines showed flexibility in multivalent designs and targeted delivery strategies that support germinal center reactions and neutralizing antibody generation
In cancer applications, circular RNA vaccines focused on inducing potent CD8+ T cell immunity and enabling combination immunotherapy approaches
๐งฌ Single-component delivery system simplifies mRNA vaccine manufacturing
Scientists created ionizable amphiphilic Janus dendrimers (IAJD) that self-assemble into a one-component delivery system, eliminating the need for complex four-component lipid nanoparticles
IAJD97 formulated with norovirus mRNA efficiently delivered vaccines to spleen and lymph nodes, demonstrating the potential for rapid global distribution during pandemics
This single-component system simplifies synthesis, reduces development complexity, and could enable faster vaccine deployment
๐ Low-dose multivalent COVID vaccines outperform high-dose single-strain versions
A low-dose trivalent mRNA vaccine elicited broadly cross-reactive antibodies against various SARS-CoV-2 variants at higher levels than a high-dose monovalent vaccine
Combining low-dose trivalent mRNA with spike proteins from multiple variants further increased cross-reactive antibody levels and neutralizing activity
Co-administering low doses of SARS-CoV-2 spike mRNA with inactivated influenza vaccines significantly enhanced immunogenicity and efficacy against influenza
๐งช Engineered lipid nanoparticles target lymph nodes while avoiding liver
New aromatic bioreducible ionizable lipids created LNPs that accumulate in and transfect lymph nodes while minimizing off-target liver accumulation
These aromatic LNPs induced stronger antigen-specific immune responses, increased effector memory T cell generation, and decreased terminal effector T cell generation in a SARS-CoV-2 vaccine study
The particles were strongly retained at injection sites and induced low levels of systemic inflammatory cytokines
๐ฌ Real-time monitoring system tracks mRNA production during manufacturing
Scientists developed a Raman spectroscopy system that simultaneously monitors ATP, CTP, GTP, UTP, and mRNA concentrations during in vitro transcription with prediction accuracy of Rยฒ 0.82-0.99
The method achieved relative errors of 4%-13%, comparable to reference offline assays (10%-12%), and worked across different mRNA sequences without recalibration
This real-time monitoring could support transition toward continuous processing and automated manufacturing systems
Implications
These advances collectively address mRNA vaccines' biggest challenges: storage requirements, manufacturing complexity, and delivery precision. From freeze-dried formulations that work at fridge temperature to single-component delivery systems and real-time manufacturing monitoring, the field is rapidly solving the practical barriers that limit global vaccine access and effectiveness.
Studies in this issue
Primary sources used for this newsletter.
- Freeze-Drying to Keep mRNA Lipid Nanoparticles Stable for a Long Timemain storyVaccines2026-03-27PMID 41893779
- Using enzymes to map pseudouridine changes across all RNA transcriptskey findingNature communications2026-03-24PMID 41872172
- Circular RNA as a New Type of Vaccine: Key Points, Challenges, and Future Outlookkey findingVaccines2026-03-27PMID 41893758
- Special mRNA lipid nanoparticles that avoid the liver target lymph nodes and trigger strong immune responseskey findingJournal of the American Chemical Society2026-03-24PMID 41873855
- Single-part molecules with both water-loving and water-repelling sides as carriers for effective mRNA vaccine deliverykey findingScience advances2026-03-27PMID 41894505
- Real-Time Tracking of mRNA Production in the Lab Using Raman Spectroscopykey findingBiotechnology and bioengineering2026-03-24PMID 41872667
- Low-dose multivalent COVID-19 mRNA vaccines boost broad antibody response and improve protection when given with protein-based vaccineskey findingVirology2026-03-27PMID 41894905
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.